---
title: "Lilly inks agreement with South Korean RNAi developer for MASH asset"
date: "2025-02-10 23:44:13"
summary: "South Korea's OliX Pharmaceuticals has negotiated a global licensing deal with Eli Lilly (NYSE:LLY) for the former's RNAi candidate for metabolic-associated steatohepatitis (MASH), OLX75016. Terms call for Lilly to provide funding to complete the Phase 1 trial. Although financial terms were not disclosed, Korea Biomedical Review said the agreement could..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503208/image_521503208.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* South Korea's OliX Pharmaceuticals has negotiated a global licensing deal with Eli Lilly (NYSE:[LLY](https://seekingalpha.com/symbol/LLY "Eli Lilly and Company")) for the former's RNAi candidate for metabolic-associated steatohepatitis (MASH), OLX75016.
* Terms call for Lilly to provide funding to complete the Phase 1 trial. Although financial terms were not disclosed, *[Korea Biomedical Review](https://www.koreabiomed.com/news/articleView.html?idxno=26559 "Korea Biomedical Review")* said the agreement could be worth up to $630M.
* OliX [said](https://www.businesswire.com/news/home/20250210958713/en/OliX-and-Lilly-Enter-Global-Licensing-Agreement-for-MASH-and-Other-Cardiometabolic-Indications "said") that OLX75016 is under investigation for MASH, liver fibrosis, and other cardiometabolic indications.

[seekalpha](https://seekingalpha.com/news/4405764-lilly-inks-agreement-south-korean-rnai-developer-olix-mash-asset)
